Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 54 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Bekiari, Eleni [Clear All Filters]
Complications of Diabetes 2017..
J Diabetes Res. 2018, 3086167.
(2018). In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER.
Annals of Internal Medicine. 168(8), JC46.
(2018). In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER..
Ann Intern Med. 168(8), JC46.
(2018). Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis..
Diabetes Obes Metab. 20(9), 2255-2263.
(2018). Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes, Obesity and Metabolism.
(2018). Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus..
Rheumatol Int. 37(2), 293-298.
(2017). Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis..
Eur J Haematol. 98(6), 563-568.
(2017). Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.
European Journal of Haematology. 98111125151171328622526459851317339343312102118301141312212432349259292117201512520158233100(6), 563 - 568.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis..
Endocrine. 56(3), 485-494.
(2017). Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Endocrine. 5625815134372239371731583439396341596(31134341111109129114943), 485 - 494.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations.
The Lancet Diabetes & Endocrinology. 5(9), 685.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations..
Lancet Diabetes Endocrinol. 5(9), 685.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis..
Expert Opin Pharmacother. 18(9), 843-851.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.
(2017). Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis.
Endocrine. 541493253564319603435853315343646323232332378366375452107937693091093863(331029229844492951104144411978855372514249), 620 - 633.
(2016). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications..
Ther Adv Drug Saf. 7(2), 36-8.
(2016). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.
Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
(2016). Most add-on therapies to metformin have similar effects on HbA1c..
Evid Based Med. 21(6), 223.
(2016). Premixed insulin regimens for type 2 diabetes.
Endocrine. 5128136293852682932172681092030295868(321Suppl 2811036512641555321), 387 - 389.
(2016). Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Endocrine. 458 - 480.
(2016). Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia..
Ann Intern Med. 163(3), 241.
(2015). Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus..
Ther Adv Endocrinol Metab. 6(2), 61-7.
(2015).
(2014).